Suppr超能文献

循环 SERPINA3 可改善新发或恶化心力衰竭患者的预后分层。

Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure.

机构信息

Cardiovascular Center, OLV Hospital, Moorselbaan 164, Aalst, 9300, Belgium.

Department of Advanced Biomedical Sciences, University of Naples Frederico II, Naples, Italy.

出版信息

ESC Heart Fail. 2021 Dec;8(6):4780-4790. doi: 10.1002/ehf2.13659. Epub 2021 Nov 1.

Abstract

AIMS

We investigated the prognostic relevance of serpin peptidase inhibitor, clade A member 3 (SERPINA3) in patients admitted with a de novo or worsened heart failure (HF).

METHODS AND RESULTS

In the first stage, 83 HF-related left ventricular (LV) transcripts were examined in patients with congestive cardiomyopathy (CCMP, n = 44) who died within 5 years and compared with age-matched and haemodynamically matched CCMP survivors (n = 39) and controls with normal LV function (n = 17). Among 14 differentially expressed transcripts, myocardial gene and circulating SERPINA3 levels were up-regulated in non-survivors vs. survivors (2.40 ± 3.66 vs. 0.36 ± 0.22 units, P < 0.01 and 334.7 ± 138.7 vs. 228.2 ± 83.1 μg/mL, P < 0.01, respectively). While no significant transmyocardial gradient was detected, cytokine stimulation of human endothelial cells induced SERPINA3 secretion. In an independent validation cohort with a de novo or worsened HF (n = 387), circulating SERPINA3 levels > 316 μg/mL were associated with increased all-cause mortality {hazard ratio [HR] [95% confidence interval (CI)]: 2.4 [1.5-3.9], P = 0.0002} and its composite with unplanned cardiovascular readmission [HR (95% CI): 2.0 (1.2-3.3), P = 0.004]. Patients with elevated SERPINA3 levels and elevated either N-terminal pro brain natriuretic peptide or ST2 showed worse freedom from both endpoints. In a multivariate analysis, including established clinical risk factors, SERPINA3 remained independent predictor of all-cause mortality together with age, gender, ST2, glomerular filtration, and pulmonary capillary wedge pressure.

CONCLUSION

In patients with a de novo or worsened HF, increased SERPINA3 levels > 316 μg/mL are associated with increased mortality or unplanned cardiac readmission. Elevated SERPINA3 levels on top of established clinical predictors appear to identify a subgroup of HF patients at higher mortality risk. Prospective studies should further validate its value in prognostic stratification of HF.

摘要

目的

我们研究了丝氨酸蛋白酶抑制剂,A 族成员 3(SERPINA3)在新发或恶化心力衰竭(HF)患者中的预后相关性。

方法和结果

在第一阶段,我们在充血性心肌病(CCMP)患者中检查了 83 个与左心室(LV)相关的 HF 转录本,这些患者在 5 年内死亡,并与年龄匹配和血流动力学匹配的 CCMP 幸存者(n=39)和 LV 功能正常的对照组(n=17)进行比较。在 14 个差异表达的转录本中,与幸存者相比,非幸存者的心肌基因和循环 SERPINA3 水平升高(2.40±3.66 与 0.36±0.22 单位,P<0.01 和 334.7±138.7 与 228.2±83.1μg/mL,P<0.01)。虽然没有检测到明显的跨心肌梯度,但人内皮细胞的细胞因子刺激诱导 SERPINA3 分泌。在一个具有新发或恶化 HF 的独立验证队列中(n=387),循环 SERPINA3 水平>316μg/mL 与全因死亡率增加相关[危险比(HR)[95%置信区间(CI)]:2.4[1.5-3.9],P=0.0002]及其复合无计划心血管再入院[HR(95%CI):2.0(1.2-3.3),P=0.004]。SERPINA3 水平升高且 N 端脑利钠肽或 ST2 升高的患者在两个终点的无事件生存方面均较差。在包括既定临床危险因素的多变量分析中,SERPINA3 仍然是全因死亡率的独立预测因素,与年龄、性别、ST2、肾小球滤过率和肺毛细血管楔压相关。

结论

在新发或恶化 HF 的患者中,SERPINA3 水平升高>316μg/mL 与死亡率或无计划的心脏再入院增加相关。在既定的临床预测因子基础上升高 SERPINA3 水平似乎可以识别 HF 患者中死亡率较高的亚组。前瞻性研究应进一步验证其在 HF 预后分层中的价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d21d/8712810/bcc71563c556/EHF2-8-4780-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验